EIOCC IO Toxicity Tool
Developed in collaboration with ONCOassist, the EIOCC IO Toxicity Tool integrates guideline recommendations on the management of immune-related adverse events (irAEs) from the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), and Society for Immunotherapy of Cancer (SITC).
All ONCOassist tools are designed by oncologists for oncologists. To develop the IO Toxicity Tool, a team of ONCOassist medical oncologists and the EIOCC scientific team reviewed the ESMO, ASCO/NCCN, and SITC guidelines and constructed streamlined algorithms for irAE management. With concise guidance, the IO Toxicity Tool helps oncologists, nurses, and other members of the cancer team make evidence-based decisions at the point of care.
Algorithms for specific toxicities may include a range of options (e.g., starting doses for corticosteroid therapy) to reflect the spectrum of recommendations within the source guidelines. Such ranges are intended to support individualize care for patients treated with IO agents. In rare cases where ESMO, ASCO/NCCN, and SITC offer divergent recommendations for irAE management, the IO Toxicity Tool defers to the ESMO guideline and notes this preference.
Guidelines for irAE Managment
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. Published February 2018.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Management of immunotherapy-related toxicities. Version 1.2018. Published February 2018.
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Published November 2017.
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines. Published July 2017.